subscribeSubscribe
DifGen Pharmaceuticals Successfully Launches A Second Product - Buprenorphine

DifGen Pharmaceuticals Successfully Launches A Second Product - Buprenorphine
PR NEWSWIRE
02 Nov 2023
Share Share
Indivior to fork over $385M in Suboxone antitrust settlement

Indivior to fork over $385M in Suboxone antitrust settlement
Zoey Becker FIERCE PHARMA
24 Oct 2023
Share Share
IntelGenx Provides Regulatory Update for Buprenorphine Buccal Film

IntelGenx Provides Regulatory Update for Buprenorphine Buccal Film
GLOBENEWSWIRE
19 Sep 2023
Share Share
Orexo`s patent win for ZUBSOLV® appealed

Orexo`s patent win for ZUBSOLV® appealed
PR NEWSWIRE
24 Jul 2023
Share Share
Orexo wins patent litigation for ZUBSOLV® in the US

Orexo wins patent litigation for ZUBSOLV® in the US
PR NEWSWIRE
01 Jul 2023
Share Share
Over 40% of U.S. Pharmacies Report No Buprenorphine in Stock

Over 40% of U.S. Pharmacies Report No Buprenorphine in Stock
GLOBENEWSWIRE
07 Jun 2023
Share Share
FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
PR NEWSWIRE
24 May 2023
Share Share
IntelGenx Announces Receipt of CRL from the FDA for Xiromed Buprenorphine

IntelGenx Announces Receipt of CRL from the FDA for Xiromed Buprenorphine
GLOBENEWSWIRE
27 Apr 2023
Share Share
Clinicians Identify Buprenorphine “Spiking” In JAMA Psychiatry Study Supported

Clinicians Identify Buprenorphine “Spiking” In JAMA Psychiatry Study Supported
BUSINESSWIRE
22 Mar 2023
Share Share
Enforcement Report - Week of March 22, 2023

Enforcement Report - Week of March 22, 2023
FDA
22 Mar 2023
Share Share